Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Integra Lifesciences Holdings (IART) Leases (2019 - 2025)

Integra Lifesciences Holdings' Leases history spans 11 years, with the latest figure at $140.6 million for Q4 2025.

  • For Q4 2025, Leases fell 2.41% year-over-year to $140.6 million; the TTM value through Dec 2025 reached $140.6 million, down 2.41%, while the annual FY2025 figure was $140.6 million, 2.41% down from the prior year.
  • Leases for Q4 2025 was $140.6 million at Integra Lifesciences Holdings, up from $138.2 million in the prior quarter.
  • Across five years, Leases topped out at $156.8 million in Q3 2023 and bottomed at $81.6 million in Q1 2022.
  • The 5-year median for Leases is $144.6 million (2022), against an average of $131.4 million.
  • The largest annual shift saw Leases decreased 10.45% in 2022 before it skyrocketed 79.45% in 2023.
  • A 5-year view of Leases shows it stood at $84.5 million in 2021, then skyrocketed by 75.39% to $148.3 million in 2022, then rose by 5.33% to $156.2 million in 2023, then decreased by 7.77% to $144.0 million in 2024, then fell by 2.41% to $140.6 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Leases are $140.6 million (Q4 2025), $138.2 million (Q3 2025), and $136.6 million (Q2 2025).